Perioperative Outcomes in Transcarotid Artery Revascularization Versus Carotid Endarterectomy or Stenting Nationwide

医学 颈动脉内膜切除术 优势比 冲程(发动机) 围手术期 颈动脉支架置入术 内科学 置信区间 血运重建 共病 心脏病学 动脉内膜切除术 颈动脉疾病 狭窄 心肌梗塞 外科 冠状动脉疾病 可能性 动脉 放射科 逻辑回归
作者
Ian Ramsay,Joshua D. Burks,Victor M. Lu,Michael Silva,Ahmed Abdelsalam,Robert M. Starke,Evan Luther
出处
期刊:Operative Neurosurgery [Oxford University Press]
卷期号:25 (5): 453-460 被引量:4
标识
DOI:10.1227/ons.0000000000000865
摘要

BACKGROUND AND OBJECTIVES: Transcarotid artery revascularization (TCAR) is a newer treatment for carotid stenosis where the carotid artery is accessed directly in the neck for stenting. It is less invasive than carotid endarterectomy (CEA) and has less embolic potential than carotid artery stenting (CAS), but population-level utilization of TCAR and outcomes are currently unknown. Our study compares outcomes of TCAR with those of CEA and CAS. METHODS: The National Inpatient Database was used for years 2015 to 2019. A multivariate logistic regression model was used to compare CEA, CAS, and TCAR outcomes with age, sex, race, hospital teaching status, symptomatic carotid disease status, side of procedure, intraoperative monitoring, and the weighted Elixhauser comorbidity score as covariates. RESULTS: TCAR comprised 0.69% of these procedures in 2016, rising to 1.35% in 2019. The inpatient rates of death, stroke, and myocardial infarction for TCAR were 0.63% (95% confidence interval: 0.36%, 1.06%), 0.42% (0.21%, 0.80%), and 1.46% (1.04%, 2.05%), respectively. Compared with CEA, TCAR had statistically insignificant difference odds of death, odds ratio (95% CI) for stroke was 0.47 (0.25, 0.87), and for myocardial infarction, it was 0.66 (0.37, 0.94). Compared with CAS, for TCAR, the odds ratio for death was 0.41 (0.24, 0.71), and for stroke, it was 0.48 (0.26, 0.91). CONCLUSION: TCAR is underutilized relative to other revascularization techniques yet has favorable outcomes compared with CEA and CAS. TCAR may be preferred to CAS in patients not surgical candidates for CEA and has a less invasive possibility for those eligible for CEA.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
蓝天应助niko采纳,获得10
刚刚
愉快天亦发布了新的文献求助10
1秒前
zhanlan发布了新的文献求助10
2秒前
Aries完成签到,获得积分20
2秒前
勤奋橘子完成签到,获得积分10
3秒前
SciGPT应助leiyuekai采纳,获得10
3秒前
4秒前
缓慢凤凰发布了新的文献求助10
4秒前
烟花应助香菜头采纳,获得30
6秒前
量子星尘发布了新的文献求助10
7秒前
wanci应助zzh采纳,获得10
8秒前
9秒前
天天快乐应助落日出逃采纳,获得10
10秒前
赵永刚完成签到,获得积分10
10秒前
Aries关注了科研通微信公众号
10秒前
阿杰完成签到,获得积分10
11秒前
柒染完成签到 ,获得积分10
13秒前
小天完成签到 ,获得积分10
14秒前
15秒前
CR7应助李嘉图采纳,获得20
15秒前
我是老大应助曹博盛采纳,获得30
16秒前
小天关注了科研通微信公众号
17秒前
hao发布了新的文献求助10
18秒前
huangman完成签到,获得积分10
20秒前
21秒前
wz完成签到,获得积分10
23秒前
之组长了完成签到 ,获得积分10
23秒前
24秒前
苏世完成签到,获得积分10
25秒前
25秒前
光亮冬寒发布了新的文献求助10
25秒前
小高完成签到 ,获得积分10
26秒前
suozi发布了新的文献求助30
26秒前
27秒前
曹博盛发布了新的文献求助30
31秒前
别当真发布了新的文献求助10
33秒前
张锐斌完成签到,获得积分20
33秒前
Azheng完成签到 ,获得积分10
34秒前
量子星尘发布了新的文献求助10
36秒前
光亮冬寒完成签到,获得积分10
36秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Encyclopedia of Reproduction Third Edition 3000
Comprehensive Methanol Science Production, Applications, and Emerging Technologies 2000
化妆品原料学 1000
《药学类医疗服务价格项目立项指南(征求意见稿)》 1000
The Political Psychology of Citizens in Rising China 600
1st Edition Sports Rehabilitation and Training Multidisciplinary Perspectives By Richard Moss, Adam Gledhill 600
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5633958
求助须知:如何正确求助?哪些是违规求助? 4729818
关于积分的说明 14987080
捐赠科研通 4791757
什么是DOI,文献DOI怎么找? 2559034
邀请新用户注册赠送积分活动 1519478
关于科研通互助平台的介绍 1479707